18889881171
Kalkine 0
countryflagUS

Baxter International Inc

Healthcare US BAX

30.305USD
-0.125(0.41%)

Last update at 2025-05-22T16:54:00Z

Day Range

30.0730.52
LowHigh

52 Week Range

28.3443.07
LowHigh

Fundamentals

  • Previous Close 30.43
  • Market Cap16073.31M
  • Volume1029419
  • P/E Ratio125.92
  • Dividend Yield2.19%
  • EBITDA2744.00M
  • Revenue TTM15062.00M
  • Revenue Per Share TTM29.64
  • Gross Profit TTM 5643.00M
  • Diluted EPS TTM0.25

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -2353.00000M 1477.00M 1292.00M 970.00M 1693.00M
Minority interest 12.00M 11.00M 8.00M -10.00000M 22.00M
Net income -2421.00000M 1284.00M 1102.00M 1001.00M 1624.00M
Selling general administrative 3862.00M 2878.00M 2469.00M 3290.00M 48.00M
Selling and marketing expenses 25.00M -11.00000M - - 2617.00M
Gross profit 5397.00M 5105.00M 4587.00M 4761.00M 4781.00M
Reconciled depreciation 1403.00M 890.00M 823.00M 789.00M 785.00M
Ebit -549.00000M 779.00M 603.00M 976.00M 953.00M
Ebitda 854.00M 1669.00M 1426.00M 1765.00M 1738.00M
Depreciation and amortization 1403.00M 890.00M 823.00M 789.00M 785.00M
Non operating income net other -15.00000M -41.00000M -190.00000M -731.00000M 139.00M
Operating income -549.00000M 779.00M 603.00M 976.00M 1599.00M
Other operating expenses 14244.00M 11074.00M 10057.00M 10486.00M 9528.00M
Interest expense 395.00M 192.00M 134.00M 111.00M 45.00M
Tax provision 68.00M 182.00M 182.00M -41.00000M 63.00M
Interest income 20.00M 192.00M 134.00M 40.00M 48.00M
Net interest income -395.00000M -192.00000M -134.00000M -71.00000M -45.00000M
Extraordinary items - 0.00000M 0.00000M 194.00M 201.00M
Non recurring 2812.00M - - - -
Other items - - - - -
Income tax expense 68.00M 182.00M 182.00M -41.00000M 63.00M
Total revenue 15113.00M 12784.00M 11673.00M 11362.00M 11127.00M
Total operating expenses 4528.00M 3395.00M 2971.00M 3885.00M 3182.00M
Cost of revenue 9716.00M 7679.00M 7086.00M 6601.00M 6346.00M
Total other income expense net -1804.00000M 698.00M 689.00M -6.00000M 139.00M
Discontinued operations - - - - -6.00000M
Net income from continuing ops -2421.00000M 1295.00M 1110.00M 1011.00M 1630.00M
Net income applicable to common shares -2433.00000M 1284.00M 1102.00M 1001.00M 1624.00M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 28276.00M 28287.00M 33521.00M 20019.00M 18193.00M
Intangible assets 6079.00M 6793.00M 7792.00M 1671.00M 1471.00M
Earning assets - - - - -
Other current assets 839.00M 399.00M 390.00M 342.00M 389.00M
Total liab 19808.00M 22392.00M 24400.00M 11293.00M 10281.00M
Total stockholder equity 8402.00M 5833.00M 9077.00M 8689.00M 7882.00M
Deferred long term liab - 119.00M 99.00M 68.00M -
Other current liab 2050.00M 1917.00M 2189.00M 1773.00M 1696.00M
Common stock 683.00M 683.00M 683.00M 683.00M 683.00M
Capital stock 683.00M 683.00M 683.00M 683.00M 683.00M
Retained earnings 16114.00M 14050.00M 17065.00M 16328.00M 15718.00M
Other liab - 1959.00M 2493.00M 1673.00M 1680.00M
Good will 6514.00M 6843.00M 9836.00M 3217.00M 3030.00M
Other assets - 653.00M 835.00M 1260.00M 983.00M
Cash 3194.00M 1718.00M 2951.00M 3730.00M 3335.00M
Cash and equivalents - 1718.00M 2951.00M 3730.00M 3335.00M
Total current liabilities 6503.00M 4745.00M 4236.00M 3333.00M 3230.00M
Current deferred revenue 148.00M 164.00M 162.00M - -
Net debt 11170.00M 15495.00M 15359.00M 3074.00M 2626.00M
Short term debt 2796.00M 1525.00M 639.00M 517.00M 642.00M
Short long term debt 2668.00M 1404.00M 511.00M 406.00M 541.00M
Short long term debt total 14364.00M 17213.00M 18310.00M 6804.00M 5961.00M
Other stockholder equity -4841.00000M -5067.00000M -5291.00000M -5008.00000M -4809.00000M
Property plant equipment - 5529.00M 5808.00M 4722.00M 4512.00M
Total current assets 9600.00M 8011.00M 8872.00M 8411.00M 7503.00M
Long term investments 194.00M 247.00M 154.00M 135.00M 76.00M
Net tangible assets - -7803.00000M 3796.00M 3801.00M 3381.00M
Short term investments - - - - -
Net receivables 2743.00M 2752.00M 2713.00M 2077.00M 1896.00M
Long term debt 11130.00M 15232.00M 17081.00M 5786.00M 4809.00M
Inventory 2824.00M 2718.00M 2453.00M 1916.00M 1653.00M
Accounts payable 1241.00M 1139.00M 1246.00M 1043.00M 892.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - 62.00M 44.00M 37.00M 30.00M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -3554.00000M -3833.00000M -3380.00000M -3314.00000M -3710.00000M
Additional paid in capital - - - - -
Common stock total equity - 683.00M 683.00M 683.00M 683.00M
Preferred stock total equity - - - - -
Retained earnings total equity - 14050.00M 17065.00M 16328.00M 15718.00M
Treasury stock - -11389.00000M -11488.00000M -11051.00000M -10764.00000M
Accumulated amortization - - - - -
Non currrent assets other 548.00M 584.00M 683.00M 512.00M 372.00M
Deferred long term asset charges - - - - -
Non current assets total 18676.00M 20276.00M 24649.00M 11608.00M 10690.00M
Capital lease obligations 566.00M 577.00M 650.00M 612.00M 611.00M
Long term debt total - 15232.00M 17149.00M 5786.00M 4809.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -931.00000M -11200.00000M -1179.00000M -1100.00000M -938.00000M
Change to liabilities -349.00000M 212.00M 143.00M -212.00000M 53.00M
Total cashflows from investing activities -931.00000M -11200.00000M -1179.00000M -1100.00000M -938.00000M
Net borrowings -899.00000M 9228.00M 478.00M 1883.00M -5.00000M
Total cash from financing activities -1438.00000M 8245.00M -345.00000M 498.00M -2603.00000M
Change to operating activities -440.00000M -58.00000M -127.00000M -152.00000M -99.00000M
Net income -2421.00000M 1295.00M 1110.00M 1011.00M 1630.00M
Change in cash -1234.00000M -780.00000M 401.00M 1497.00M -1562.00000M
Begin period cash flow 2956.00M 3736.00M 3335.00M 1838.00M 3394.00M
End period cash flow 1722.00M 2956.00M 3736.00M 3335.00M 1832.00M
Total cash from operating activities 1211.00M 2222.00M 1868.00M 2104.00M 2096.00M
Issuance of capital stock - - - - -
Depreciation 1403.00M 890.00M 823.00M 789.00M 785.00M
Other cashflows from investing activities -252.00000M -10457.00000M -470.00000M -404.00000M -257.00000M
Dividends paid -573.00000M -530.00000M -473.00000M -423.00000M 376.00M
Change to inventory -361.00000M -37.00000M -162.00000M 4.00M -197.00000M
Change to account receivables -146.00000M -170.00000M -126.00000M -65.00000M -12.00000M
Sale purchase of stock -32.00000M -600.00000M -500.00000M -1270.00000M -2452.00000M
Other cashflows from financing activities 121.00M -138.00000M -52.00000M 2191.00M -28.00000M
Change to netincome 3085.00M -26.00000M 172.00M 555.00M -99.00000M
Capital expenditures 679.00M 743.00M 709.00M 696.00M 681.00M
Change receivables -146.00000M -170.00000M -126.00000M -65.00000M -12.00000M
Cash flows other operating - 58.00M -92.00000M 22.00M -58.00000M
Exchange rate changes - - - - -117.00000M
Cash and cash equivalents changes -1158.00000M -733.00000M 344.00M 1502.00M -1562.00000M
Change in working capital -1023.00000M -161.00000M -272.00000M -425.00000M -360.00000M
Stock based compensation 154.00M 146.00M 130.00M 122.00M 115.00M
Other non cash items 3323.00M 198.00M 165.00M 917.00M 193.00M
Free cash flow 532.00M 1479.00M 1159.00M 1408.00M 1415.00M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BAX
Baxter International Inc		 -0.125 0.41% 30.30 125.92 12.82 1.07 2.01 1.83 15.09
ISRG
Intuitive Surgical Inc		 -3.81 0.70% 543.26 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA		 1.94 1.32% 148.50 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme		 1.00 0.34% 296.00 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company		 -0.63 0.36% 172.51 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

View All

Profile

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Baxter International Inc

One Baxter Parkway, Deerfield, IL, United States, 60015

Key Executives

Name Title Year Born
Mr. Jose E. Almeida Chairman, Pres & CEO 1962
Mr. James K. Saccaro Exec. VP & CFO 1973
Mr. Giuseppe Accogli Exec. VP & COO 1971
Mr. Andrew Frye Pres of Patient Support Systems, Global Surgical Solutions & Enterprise Connectivity 1965
Mr. Cristiano Franzi Sr. VP & Pres for EMEA 1963
Mr. Brian C. Stevens Sr. VP, Chief Accounting Officer & Controller 1975
Mr. Talvis P. Love Sr. VP & Chief Information Officer 1968
Ms. Clare Trachtman VP of Investor Relations NA
Mr. David S. Rosenbloom Sr. VP & Gen. Counsel NA
Ms. Stacey Eisen Sr. VP of Global Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.